LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Akciju saraksts・AnaptysBio Inc

AnaptysBio Inc

Slēgts

SektorsVeselības aprūpe

51.64 0.55

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

50.43

Max

52.65

Galvenie mērījumi
By Trading Economics
Ienākumi	-102M -53M
Pārdošana	-83M 26M
EPS	-1.843
Peļņas marža	-206.934
Darbinieki	104
EBITDA	-102M -34M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+47.41% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-482M 1.5B
Iepriekšējā atvēršanas cena	51.09
Iepriekšējā slēgšanas cena	51.64

Ziņu noskaņojums

By Acuity

50%

153 / 344 Rangs Healthcare

AnaptysBio Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. jūn. 23:49 UTC

Tirgus saruna

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

2026. g. 9. jūn. 23:45 UTC

Iegādes, apvienošanās, pārņemšana

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

2026. g. 9. jūn. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

2026. g. 9. jūn. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

2026. g. 9. jūn. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

2026. g. 9. jūn. 23:35 UTC

Tirgus saruna

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

2026. g. 9. jūn. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Additional Investment Makes It Largest Shareholder in Element

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

2026. g. 9. jūn. 20:51 UTC

Peļņas

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 9. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. jūn. 20:09 UTC

Tirgus saruna

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

2026. g. 9. jūn. 19:36 UTC

Tirgus saruna

Cattle Climbs as Crude Oil Falls -- Market Talk

2026. g. 9. jūn. 19:32 UTC

Tirgus saruna

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

2026. g. 9. jūn. 19:25 UTC

Tirgus saruna

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

2026. g. 9. jūn. 19:00 UTC

Tirgus saruna

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

2026. g. 9. jūn. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

2026. g. 9. jūn. 18:47 UTC

Tirgus saruna

No World Cup Inflation Seen So Far in Mexico -- Market Talk

2026. g. 9. jūn. 18:37 UTC

Tirgus saruna

Canada's Cooling Trade With the U.S. -- Market Talk

2026. g. 9. jūn. 18:27 UTC

Tirgus saruna

Precious Metals Lower as Trump Vows Military Response -- Market Talk

2026. g. 9. jūn. 17:35 UTC

Tirgus saruna

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

2026. g. 9. jūn. 17:30 UTC

Tirgus saruna

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

2026. g. 9. jūn. 16:34 UTC

Tirgus saruna

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2026. g. 9. jūn. 15:28 UTC

Tirgus saruna

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

2026. g. 9. jūn. 15:25 UTC

Tirgus saruna

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Salīdzinājums

Cenas izmaiņa

AnaptysBio Inc Prognoze

Cenas mērķis

By TipRanks

47.41% augšup

Prognoze 12 mēnešiem

Vidējais 75.71 USD 47.41%

Augstākais 93 USD

Zemākais 66 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

153 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.